 | • レポートコード：MRC22NVL19124 • 出版社/出版日：LP Information / 2022年10月 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥541,680 (USD3,660) | ▷ お問い合わせ |
| Corporate User | ￥1,083,360 (USD7,320) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 世界経済が回復するにつれて、2021年の院内肺炎（HAP）治療薬の成長は前年から大幅に変化します。LP Information社（米国）の最新の調査によると、世界の院内肺炎（HAP）治療薬市場規模は、2021年の000ドルから2022年には000ドルに達し、2021年～2022年間に000%の成長が予想されます。2028年には世界の院内肺炎（HAP）治療薬市場規模が000ドルまで成長し、調査期間中に000%の年平均成長率を記録すると予想されます。 米国の院内肺炎（HAP）治療薬市場は2021年に000ドルの市場規模が見込まれ、調査期間中は約000%の年平均成長率で成長すると予測されます。中国は世界の院内肺炎（HAP）治療薬市場の000%のシェアを占め、2028年までに000ドルに達すると展望されます。欧州の院内肺炎（HAP）治療薬の状況については、ドイツが2028年までに000ドルに達し、調査期間にわたって年平均成長率が000%になると予測されます。アジア地域では、日本と韓国の成長率が、今後5年間でそれぞれ000%と000%になると展望されます。 世界の主要な院内肺炎（HAP）治療薬プレーヤーとして、Basilea Pharmaceutica、 Meiji Holdings、 Cubist Pharmaceutical、 Aridis Pharmaceutical、 Valneva、 Bayer、 GlaxoSmithKline、 Merck、 Achaogen、 AstraZenecaなどをカバーしています。売上の面では、世界のトップ2社が2021年に約000%市場シェアを占めています。 当レポートでは、製品タイプ、用途（アプリケーション）、主要メーカー、主要地域および国ごとの院内肺炎（HAP）治療薬市場の包括的な概要、市場シェア、および成長機会を掲載します。 タイプ別のセグメンテーション：2017年～2022年までの内訳データと2028年まで予測データ 第Ⅱ相、初期段階（第Ⅰ＆Ⅱ相） 用途（アプリケーション）別のセグメンテーション：2017年～2022年までの内訳データと2028年まで予測データ 病院薬局、薬局、ドラッグストア、EC 当レポートは次の地域と国の市場規模データを掲載します。 南北アメリカ（米国、カナダ、メキシコ、ブラジル） アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア） 欧州（ドイツ、フランス、イギリス、イタリア、ロシア） 中東/アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国） ********* 目次 ********* レポートの範囲 ・市場の紹介 ・分析対象期間 ・調査の目的 ・調査手法 ・調査プロセスおよびデータソース ・経済指標 ・通貨 エグゼクティブサマリー ・世界市場の概要：院内肺炎（HAP）治療薬の年間販売量2017-2028、地域別現状・将来分析 ・院内肺炎（HAP）治療薬のタイプ別セグメント：第Ⅱ相、初期段階（第Ⅰ＆Ⅱ相） ・院内肺炎（HAP）治療薬のタイプ別販売量：2017-2022年の販売量、売上、市場シェア、販売価格 ・院内肺炎（HAP）治療薬の用途別セグメント：病院薬局、薬局、ドラッグストア、EC ・院内肺炎（HAP）治療薬の用途別販売量：2017-2022年の販売量、売上、市場シェア、販売価格 企業別世界の院内肺炎（HAP）治療薬市場 ・企業別のグローバル院内肺炎（HAP）治療薬市場データ：2020-2022年の年間販売量、市場シェア ・企業別の院内肺炎（HAP）治療薬の年間売上：2020-2022年の売上、市場シェア ・企業別の院内肺炎（HAP）治療薬販売価格 ・主要企業の院内肺炎（HAP）治療薬生産地域、販売地域、製品タイプ ・市場集中度分析 ・新製品および潜在的な参加者 ・合併と買収、拡大 院内肺炎（HAP）治療薬の地域別レビュー ・地域別の院内肺炎（HAP）治療薬市場規模2017-2022：年間販売量、売上 ・主要国別の院内肺炎（HAP）治療薬市場規模2017-2022：年間販売量、売上 ・南北アメリカの院内肺炎（HAP）治療薬販売の成長 ・アジア太平洋の院内肺炎（HAP）治療薬販売の成長 ・欧州の院内肺炎（HAP）治療薬販売の成長 ・中東・アフリカの院内肺炎（HAP）治療薬販売の成長 南北アメリカ市場 ・南北アメリカの国別の院内肺炎（HAP）治療薬販売量、売上（2017-2022） ・南北アメリカの院内肺炎（HAP）治療薬の種類別販売量 ・南北アメリカの院内肺炎（HAP）治療薬の用途別販売量 ・米国の院内肺炎（HAP）治療薬市場 ・カナダの院内肺炎（HAP）治療薬市場 ・メキシコの院内肺炎（HAP）治療薬市場 ・ブラジルの院内肺炎（HAP）治療薬市場 アジア太平洋市場 ・アジア太平洋の国別の院内肺炎（HAP）治療薬販売量、売上（2017-2022） ・アジア太平洋の院内肺炎（HAP）治療薬の種類別販売量 ・アジア太平洋の院内肺炎（HAP）治療薬の用途別販売量 ・中国市場の院内肺炎（HAP）治療薬市場 ・日本市場の院内肺炎（HAP）治療薬市場 ・韓国市場の院内肺炎（HAP）治療薬市場 ・東南アジアの院内肺炎（HAP）治療薬市場 ・インドの院内肺炎（HAP）治療薬市場 ・オーストラリアの院内肺炎（HAP）治療薬市場 ・台湾の院内肺炎（HAP）治療薬市場 欧州市場 ・欧州の国別の院内肺炎（HAP）治療薬販売量、売上（2017-2022） ・欧州の院内肺炎（HAP）治療薬の種類別販売量 ・欧州の院内肺炎（HAP）治療薬の用途別販売量 ・ドイツの院内肺炎（HAP）治療薬市場 ・フランスの院内肺炎（HAP）治療薬市場 ・イギリスの院内肺炎（HAP）治療薬市場 ・イタリアの院内肺炎（HAP）治療薬市場 ・ロシアの院内肺炎（HAP）治療薬市場 中東・アフリカ市場 ・中東・アフリカの国別の院内肺炎（HAP）治療薬販売量、売上（2017-2022） ・中東・アフリカの院内肺炎（HAP）治療薬の種類別販売量 ・中東・アフリカの院内肺炎（HAP）治療薬の用途別販売量 ・エジプトの院内肺炎（HAP）治療薬市場 ・南アフリカの院内肺炎（HAP）治療薬市場 ・イスラエルの院内肺炎（HAP）治療薬市場 ・トルコの院内肺炎（HAP）治療薬市場 ・GCC諸国の院内肺炎（HAP）治療薬市場 市場の成長要因、課題、動向 ・市場の成長要因および成長機会分析 ・市場の課題およびリスク ・市場動向 製造コスト構造分析 ・原材料とサプライヤー ・院内肺炎（HAP）治療薬の製造コスト構造分析 ・院内肺炎（HAP）治療薬の製造プロセス分析 ・院内肺炎（HAP）治療薬の産業チェーン構造 マーケティング、販売業者および顧客 ・販売チャンネル：直接販売チャンネル、間接販売チャンネル ・院内肺炎（HAP）治療薬の主要なグローバル販売業者 ・院内肺炎（HAP）治療薬の主要なグローバル顧客 地域別の院内肺炎（HAP）治療薬市場予測レビュー ・地域別の院内肺炎（HAP）治療薬市場規模予測（2023-2028） ・南北アメリカの国別予測 ・アジア太平洋の国別予測 ・欧州の国別予測 ・院内肺炎（HAP）治療薬のタイプ別市場規模予測 ・院内肺炎（HAP）治療薬の用途別市場規模予測 主要企業分析 Basilea Pharmaceutica、 Meiji Holdings、 Cubist Pharmaceutical、 Aridis Pharmaceutical、 Valneva、 Bayer、 GlaxoSmithKline、 Merck、 Achaogen、 AstraZeneca ・企業情報 ・院内肺炎（HAP）治療薬製品 ・院内肺炎（HAP）治療薬販売量、売上、価格、粗利益（2020-2022） ・主要ビジネス概要 ・最新動向 調査結果および結論 |
As the global economy mends, the 2021 growth of Hospital Acquired Pneumonia Drugs will have significant change from previous year. According to our (LP Information) latest study, the global Hospital Acquired Pneumonia Drugs market size is USD million in 2022 from USD 2746.4 million in 2021, with a change of % between 2021 and 2022. The global Hospital Acquired Pneumonia Drugs market size will reach USD 3059.9 million in 2028, growing at a CAGR of 1.6% over the analysis period.
The United States Hospital Acquired Pneumonia Drugs market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Hospital Acquired Pneumonia Drugs market, reaching US$ million by the year 2028. As for the Europe Hospital Acquired Pneumonia Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Hospital Acquired Pneumonia Drugs players cover Basilea Pharmaceutica, Meiji Holdings, Cubist Pharmaceutical, and Aridis Pharmaceutical, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Hospital Acquired Pneumonia Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Phase II
Early Phase (Phase I & II)
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital Pharmacies
Retail Pharmacies
Drug Store
E-Commerce
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Basilea Pharmaceutica
Meiji Holdings
Cubist Pharmaceutical
Aridis Pharmaceutical
Valneva
Bayer
GlaxoSmithKline
Merck
Achaogen
AstraZeneca
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hospital Acquired Pneumonia Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Hospital Acquired Pneumonia Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Hospital Acquired Pneumonia Drugs by Country/Region, 2017, 2022 & 2028
2.2 Hospital Acquired Pneumonia Drugs Segment by Type
2.2.1 Phase II
2.2.2 Early Phase (Phase I & II)
2.3 Hospital Acquired Pneumonia Drugs Sales by Type
2.3.1 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global Hospital Acquired Pneumonia Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global Hospital Acquired Pneumonia Drugs Sale Price by Type (2017-2022)
2.4 Hospital Acquired Pneumonia Drugs Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Drug Store
2.4.4 E-Commerce
2.5 Hospital Acquired Pneumonia Drugs Sales by Application
2.5.1 Global Hospital Acquired Pneumonia Drugs Sale Market Share by Application (2017-2022)
2.5.2 Global Hospital Acquired Pneumonia Drugs Revenue and Market Share by Application (2017-2022)
2.5.3 Global Hospital Acquired Pneumonia Drugs Sale Price by Application (2017-2022)
3 Global Hospital Acquired Pneumonia Drugs by Company
3.1 Global Hospital Acquired Pneumonia Drugs Breakdown Data by Company
3.1.1 Global Hospital Acquired Pneumonia Drugs Annual Sales by Company (2020-2022)
3.1.2 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Company (2020-2022)
3.2 Global Hospital Acquired Pneumonia Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global Hospital Acquired Pneumonia Drugs Revenue by Company (2020-2022)
3.2.2 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Company (2020-2022)
3.3 Global Hospital Acquired Pneumonia Drugs Sale Price by Company
3.4 Key Manufacturers Hospital Acquired Pneumonia Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hospital Acquired Pneumonia Drugs Product Location Distribution
3.4.2 Players Hospital Acquired Pneumonia Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Hospital Acquired Pneumonia Drugs by Geographic Region
4.1 World Historic Hospital Acquired Pneumonia Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global Hospital Acquired Pneumonia Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Hospital Acquired Pneumonia Drugs Annual Revenue by Geographic Region
4.2 World Historic Hospital Acquired Pneumonia Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global Hospital Acquired Pneumonia Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global Hospital Acquired Pneumonia Drugs Annual Revenue by Country/Region
4.3 Americas Hospital Acquired Pneumonia Drugs Sales Growth
4.4 APAC Hospital Acquired Pneumonia Drugs Sales Growth
4.5 Europe Hospital Acquired Pneumonia Drugs Sales Growth
4.6 Middle East & Africa Hospital Acquired Pneumonia Drugs Sales Growth
5 Americas
5.1 Americas Hospital Acquired Pneumonia Drugs Sales by Country
5.1.1 Americas Hospital Acquired Pneumonia Drugs Sales by Country (2017-2022)
5.1.2 Americas Hospital Acquired Pneumonia Drugs Revenue by Country (2017-2022)
5.2 Americas Hospital Acquired Pneumonia Drugs Sales by Type
5.3 Americas Hospital Acquired Pneumonia Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hospital Acquired Pneumonia Drugs Sales by Region
6.1.1 APAC Hospital Acquired Pneumonia Drugs Sales by Region (2017-2022)
6.1.2 APAC Hospital Acquired Pneumonia Drugs Revenue by Region (2017-2022)
6.2 APAC Hospital Acquired Pneumonia Drugs Sales by Type
6.3 APAC Hospital Acquired Pneumonia Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Hospital Acquired Pneumonia Drugs by Country
7.1.1 Europe Hospital Acquired Pneumonia Drugs Sales by Country (2017-2022)
7.1.2 Europe Hospital Acquired Pneumonia Drugs Revenue by Country (2017-2022)
7.2 Europe Hospital Acquired Pneumonia Drugs Sales by Type
7.3 Europe Hospital Acquired Pneumonia Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hospital Acquired Pneumonia Drugs by Country
8.1.1 Middle East & Africa Hospital Acquired Pneumonia Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa Hospital Acquired Pneumonia Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa Hospital Acquired Pneumonia Drugs Sales by Type
8.3 Middle East & Africa Hospital Acquired Pneumonia Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hospital Acquired Pneumonia Drugs
10.3 Manufacturing Process Analysis of Hospital Acquired Pneumonia Drugs
10.4 Industry Chain Structure of Hospital Acquired Pneumonia Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hospital Acquired Pneumonia Drugs Distributors
11.3 Hospital Acquired Pneumonia Drugs Customer
12 World Forecast Review for Hospital Acquired Pneumonia Drugs by Geographic Region
12.1 Global Hospital Acquired Pneumonia Drugs Market Size Forecast by Region
12.1.1 Global Hospital Acquired Pneumonia Drugs Forecast by Region (2023-2028)
12.1.2 Global Hospital Acquired Pneumonia Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Hospital Acquired Pneumonia Drugs Forecast by Type
12.7 Global Hospital Acquired Pneumonia Drugs Forecast by Application
13 Key Players Analysis
13.1 Basilea Pharmaceutica
13.1.1 Basilea Pharmaceutica Company Information
13.1.2 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Product Offered
13.1.3 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Basilea Pharmaceutica Main Business Overview
13.1.5 Basilea Pharmaceutica Latest Developments
13.2 Meiji Holdings
13.2.1 Meiji Holdings Company Information
13.2.2 Meiji Holdings Hospital Acquired Pneumonia Drugs Product Offered
13.2.3 Meiji Holdings Hospital Acquired Pneumonia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Meiji Holdings Main Business Overview
13.2.5 Meiji Holdings Latest Developments
13.3 Cubist Pharmaceutical
13.3.1 Cubist Pharmaceutical Company Information
13.3.2 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Product Offered
13.3.3 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Cubist Pharmaceutical Main Business Overview
13.3.5 Cubist Pharmaceutical Latest Developments
13.4 Aridis Pharmaceutical
13.4.1 Aridis Pharmaceutical Company Information
13.4.2 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Product Offered
13.4.3 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Aridis Pharmaceutical Main Business Overview
13.4.5 Aridis Pharmaceutical Latest Developments
13.5 Valneva
13.5.1 Valneva Company Information
13.5.2 Valneva Hospital Acquired Pneumonia Drugs Product Offered
13.5.3 Valneva Hospital Acquired Pneumonia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Valneva Main Business Overview
13.5.5 Valneva Latest Developments
13.6 Bayer
13.6.1 Bayer Company Information
13.6.2 Bayer Hospital Acquired Pneumonia Drugs Product Offered
13.6.3 Bayer Hospital Acquired Pneumonia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Bayer Main Business Overview
13.6.5 Bayer Latest Developments
13.7 GlaxoSmithKline
13.7.1 GlaxoSmithKline Company Information
13.7.2 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Product Offered
13.7.3 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 GlaxoSmithKline Main Business Overview
13.7.5 GlaxoSmithKline Latest Developments
13.8 Merck
13.8.1 Merck Company Information
13.8.2 Merck Hospital Acquired Pneumonia Drugs Product Offered
13.8.3 Merck Hospital Acquired Pneumonia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Merck Main Business Overview
13.8.5 Merck Latest Developments
13.9 Achaogen
13.9.1 Achaogen Company Information
13.9.2 Achaogen Hospital Acquired Pneumonia Drugs Product Offered
13.9.3 Achaogen Hospital Acquired Pneumonia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Achaogen Main Business Overview
13.9.5 Achaogen Latest Developments
13.10 AstraZeneca
13.10.1 AstraZeneca Company Information
13.10.2 AstraZeneca Hospital Acquired Pneumonia Drugs Product Offered
13.10.3 AstraZeneca Hospital Acquired Pneumonia Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 AstraZeneca Main Business Overview
13.10.5 AstraZeneca Latest Developments
14 Research Findings and Conclusion